Australia markets open in 7 hours 57 minutes
  • ALL ORDS

    6,893.60
    +131.20 (+1.94%)
     
  • AUD/USD

    0.6939
    -0.0013 (-0.19%)
     
  • ASX 200

    6,706.00
    +127.30 (+1.94%)
     
  • OIL

    109.16
    +1.54 (+1.43%)
     
  • GOLD

    1,826.40
    -3.90 (-0.21%)
     
  • BTC-AUD

    29,917.30
    -1,009.97 (-3.27%)
     
  • CMC Crypto 200

    452.21
    -9.58 (-2.08%)
     

Aptinyx to Participate in H.C. Wainwright Global Investment Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

EVANSTON, Ill., May 18, 2022--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022. The presentation will be available on-demand through the H.C. Wainwright conference portal, beginning at 7:00 AM ET on Tuesday, May 24, 2022.

A webcast recording of the presentation will be available to view on the "Events and Presentations" page in the "Investors & Media" section of Aptinyx’s website at https://ir.aptinyx.com and will be archived on Aptinyx’s website for 30 days following the event.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including fibromyalgia, post-traumatic stress disorder, and cognitive impairment. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com or follow Aptinyx on Twitter @Aptinyx.

Source: Aptinyx Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005502/en/

Contacts

Investor and Media Contact:
Patrick Flavin
Aptinyx Inc.
ir@aptinyx.com or corporate@aptinyx.com
847-871-0377

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting